SavedAdd your journal

Journals / Medicine Science / 2017 / Cilt: 6 - Sayı: 4

Evaluation of drug adherence in patients with non-valvular atrial fibrillation according to geographic regions of Turkey: An analysis from NOAC-TR study

SADIK VOLKAN EMREN
Mehdi ZOGHİ
Gönül AÇIKSARI
Abdullah ASLAN
Barış ÇELEBİ
Murat BİLGİN
Oktay ŞENÖZ
Ilgın KARACA
Abdurrahman AKYÜZ
Salih KILIÇ
Sinan İNCİ
Pages
689–695
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: NOAC adherence was different between geographic regions in Turkey

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Drug adherence to novel oral anticoagulants (NOAC) varied by countries and popuplations.
📊
Key Findings & Data:A total of 2802 patients (59% female) taking NOAC (Dabigatran, apixaban, rivaroxaban) due to NVAF at least 3 months, were included.
💡
Conclusion & Impact:Conclusion: NOAC adherence was different between geographic regions in Turkey
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Drug adherence to novel oral anticoagulants (NOAC) varied by countries and popuplations. As a result of NOAC-TR study, in Turkey, drug adhrence to NOACs is poor comparing to other real world studies. However it is not known whether there is a difference between geographic regions of Turkey in terms of NOAC adherence. In this study we aim to investigate the NOAC adherence in patients with non-valvular atrial fibrillation according to the geographic regions in Turkey Method: This cros-sectional study was designed as a subgroup study of NOAC-TR (Drug Adherence in patients with non valvular atrial fibrillation taking non-vitamin K antagonist oral anticoagulants in Turkey). A total of 2802 patients (59% female) taking NOAC (Dabigatran, apixaban, rivaroxaban) due to NVAF at least 3 months, were included. Morisky-8 item drug adherence scale was used. Patients were divided in 3 groups (high, moderate and low adherent) based on drug adherence Results: Of the patients 24% were adherent, 26% were moderate adhererent and 50% were low adherent to NOAC treatment. Drug adhrence was different between geographic regions (p<0,001). In post-hoc analysis low adherent rate was highest in Blacksea region (72% low adherent, 21% moderate adherent, 7% low adherent). Adherence rate was highest in Aegean (36% adherent, 26% moderate adherent 38%) and Marmara region (38% adherent, 28% moderate adherent 34% low adherent). Conclusion: NOAC adherence was different between geographic regions in Turkey

🔖

Cite This Article

EMREN, S. V., ZOGHİ, M., AÇIKSARI, G., ASLAN, A., ÇELEBİ, B., BİLGİN, M., ŞENÖZ, O., KARACA, I., AKYÜZ, A., KILIÇ, S., İNCİ, S. (2017). Evaluation of drug adherence in patients with non-valvular atrial fibrillation according to geographic regions of Turkey: An analysis from NOAC-TR study. Medicine Science, Cilt: 6 - Sayı: 4, 689–695. https://ajindex.com/articles/277380

References (12)

  1. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028-35
  2. Deykin D. Warfarin therapy. N Engl J Med. 1970;283(13):691–694
  3. Shameem R, Ansell J. Disadvantages of VKA and requirements for novel anticoagulants. Best Pract Res Clin Haematol. 2013;26(2):103–14
  4. Connolly S, Ezekowitz M, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2010;361(12):1139–51
  5. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus Warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91
  6. Granger C, Alexander J, McMurray J, Lopes R, Hylek E, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92
  7. Schulman S, Kearon C, Kakkar A, Mismetti P, Schellong S, Eriksson H. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–52
  8. Landman G, Gans R. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2011;364(36):2499–510
  9. Blann A, Lip G. Laboratory monitoring of the non-vitamin K oral anticoagulants. J Am Coll Cardiol. 2014;64(11):1140–2
  10. Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace. 2015;17(4):514–23
  11. Emren SV, Senöz O, Bilgin M, Beton O, Aslan A, Taşkın U, Açiksari G, Asarcikli LD, Çakır H, Bekar L, Bolat İ, Yayla Ç, Çelebi B, Dalgıç O,Çelik O, Şafak Ö, Akyel S, Güngör H, Düzel B, Zoghi M Drug Adherence in Patients With Nonvalvular Atrial Fibrillation Taking Non-Vitamin K Antagonist Oral Anticoagulants in Turkey: NOAC-TR DOI: 10.1177/1076029617693940 | First Published January 1, 2017 12. Davis NJ, Billett HH, Cohen HW, Arnsten JH. Impact of adherence, knowledge, and quality of life on anticoagulation control. Ann Pharmacother. 2005;39(4):632-6
  12. Morisky DE, Ang A, Krousel‐Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. J. Clin. Hypertens. 2008;10(5):348–54. 14.